A hexokinase isoenzyme switch in human liver cancer cells promotes lipogenesis and enhances innate immunity

A hexokinase isoenzyme switch in human liver cancer cells promotes lipogenesis and enhances innate immunity

Many cancers fuel their rapid growth by replacing glucokinase with its higher affinity isoenzyme, hexokinase 2 (HK2), making HK2 an attractive drug target. In this study, Perrin-Cocon and Vidalain et al. use CRISPR/Cas-9 gene editing to reverse this enzymatic switch in human liver cancer cells, and...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Laure Perrin-Cocon, Pierre-Olivier Vidalain, Clémence Jacquemin, Anne Aublin-Gex, Keedrian Olmstead, Baptiste Panthu, Gilles Jeans Philippe Rautureau, Patrice André, Piotr Nyczka, Marc-Thorsten Hütt, Nivea Amoedo, Rodrigue Rossignol, Fabian Volker Filipp, Vincent Lotteau, Olivier Diaz
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Biology (General)
QH301-705.5
Acceso en línea:https://doaj.org/article/a519b0af2fba49868394944910f843d0
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Many cancers fuel their rapid growth by replacing glucokinase with its higher affinity isoenzyme, hexokinase 2 (HK2), making HK2 an attractive drug target. In this study, Perrin-Cocon and Vidalain et al. use CRISPR/Cas-9 gene editing to reverse this enzymatic switch in human liver cancer cells, and find this restores innate immune function as well as reversing cancer-associated metabolic reprogramming.

Ejemplares similares